Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cyberonics Rejects Second ANS Bid, Considers Offer Beneath Self-Appraisal

This article was originally published in The Gray Sheet

Executive Summary

Advanced Neuromodulation Systems likely would need to up the ante to sway Cyberonics shareholders to accept a takeover bid after CEO Skip Cummins' rejection of initial offers as too low

You may also be interested in...



Cyberonics Could Be Acquisition Target With Permanent CEO Slot Left Open

Cyberonics' recent ouster of CEO Robert "Skip" Cummins could make the neurostimulation device firm an acquisition candidate for other implantable pulse generator manufacturers such as Medtronic or St. Jude Medical - both of which have made unsuccessful merger offers in the past

Cyberonics Could Be Acquisition Target With Permanent CEO Slot Left Open

Cyberonics' recent ouster of CEO Robert "Skip" Cummins could make the neurostimulation device firm an acquisition candidate for other implantable pulse generator manufacturers such as Medtronic or St. Jude Medical - both of which have made unsuccessful merger offers in the past

Cyberonics Seeks Suitor To Transform Into Premier Neuromodulation Firm

Cyberonics' aim to become the global neuromodulation leader following FDA approval of its VNS Therapy for treatment-resistant depression could depend on its attractiveness as an acquisition target

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020900

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel